• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

    11/19/21 5:08:04 PM ET
    $ODT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ODT alert in real time by email
    SC 13D/A 1 r1117212sc13da7.htm AMENDMENT NO. 7

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D/A

    Under the Securities Exchange Act of 1934

    (Amendment No. 7)*

     

     

    Odonate Therapeutics, Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.01
    (Title of Class of Securities)
     
    676079106
    (CUSIP Number)
     
    Kevin Tang
    Tang Capital Management, LLC
    4747 Executive Drive, Suite 210
    San Diego, CA 92121
    (858) 200-3830
    (Name, Address and Telephone Number of Person Authorized to
    Receive Notices and Communications)
     
    November 17, 2021
    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    (Continued on following pages)

     

     

       
     

     

    CUSIP NO. 676079106 13D Page 2 of 8

     

    1.

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only).

     

    Tang Capital Partners, LP

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ý

    3.

    SEC Use Only

     

    4.

    Source of Funds

    WC

    5.

    Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)

    ☐

    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    12,958,577

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    12,767,435

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    12,958,577

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares          ☐
    13.

    Percent of Class Represented by Amount in Row (11)

    33.7%

    14

    Type of Reporting Person

    PN

     

      Page 2 of 8 
     

     

    CUSIP NO. 676079106 13D Page 3 of 8

     

    1.

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only).

     

    Tang Capital Management, LLC

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ý

    3.

    SEC Use Only

     

    4.

    Source of Funds

    WC

    5.

    Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)

    ☐

    6.

    Citizenship or Place of Organization

    Delaware

    Number of

    Shares Beneficially

    Owned by

    Each Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    12,958,577

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    12,767,435

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    12,958,577

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares          ☐
    13.

    Percent of Class Represented by Amount in Row (11)

    33.7%

    14

    Type of Reporting Person

    OO

     

      Page 3 of 8 
     

     

    CUSIP NO. 676079106 13D Page 4 of 8

     

    1.

    Names of Reporting Persons.

    I.R.S. Identification Nos. of above persons (entities only).

     

    Kevin Tang

    2.

    Check the Appropriate Box if a Member of a Group

    (a) ☐

    (b) ý

    3.

    SEC Use Only

     

    4.

    Source of Funds

    PF, WC, OO

    5.

    Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)

    ☐

    6.

    Citizenship or Place of Organization

    United States

    Number of

    Shares Beneficially

    Owned by

    Each Reporting

    Person With

    7.

    Sole Voting Power

    0

    8.

    Shared Voting Power

    12,958,577

    9.

    Sole Dispositive Power

    0

    10.

    Shared Dispositive Power

    12,767,435

    11.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    12,958,577

    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares          ☐
    13.

    Percent of Class Represented by Amount in Row (11)

    33.7%

    14

    Type of Reporting Person

    IN

     

      Page 4 of 8 
     

     

    Explanatory Note: This Amendment No. 7 relates to and amends the Statement of Beneficial Ownership on Schedule 13D/A of Tang Capital Partners, LP, a Delaware limited partnership, Tang Capital Management, LLC, a Delaware limited liability company, and Kevin Tang, a United States citizen (each, a “Reporting Person” and collectively, the “Reporting Persons”), initially filed jointly by the Reporting Persons with the U.S. Securities and Exchange Commission (“SEC”) on December 18, 2017, and amended on August 24, 2018, November 9, 2018, March 12, 2019, June 28, 2019, September 1, 2020 and December 29, 2020 (as amended, the “Statement”), with respect to the Common Stock, $0.01 par value (the “Common Stock”), of Odonate Therapeutics, Inc., a Delaware corporation (the “Issuer”).

     

    Items 5 and 6 of the Statement are hereby amended to the extent hereinafter expressly set forth. Except as amended hereby, the original disclosure set forth in the Statement shall remain unchanged. All capitalized terms used and not expressly defined herein have the respective meanings ascribed to such terms in the Statement. 

     

    Item 5. Interest in Securities of the Issuer.

     

    The information previously provided in response to Item 5 is hereby amended and restated by replacing the text thereof in its entirety with the following:

     

    (a)           Amount beneficially owned and percentage of class:

     

    Tang Capital Partners, LP 12,958,577 shares, representing 33.7% of the class
    Tang Capital Management, LLC 12,958,577 shares, representing 33.7% of the class
    Kevin Tang 12,958,577 shares, representing 33.7% of the class

     

    Tang Capital Partners, LP is the beneficial owner of 12,958,577 shares of the Issuer’s Common Stock. Tang Capital Partners, LP shares voting and dispositive power over such shares of Common Stock with Tang Capital Management, LLC and Kevin Tang. Subject to the arrangements described in Item 6 of this Statement, the shares reported as beneficially owned by the Reporting Persons include a total of 345,427 shares of Common Stock that are held of record by Odonate Holdings, LLC (“Holdings”). Holdings has granted a proxy to Tang Capital Partners, LP giving Tang Capital Partners, LP the authority to vote 154,285 shares. Holdings has also granted a proxy to the Issuer giving the Issuer the authority to vote 567,742 shares in the same proportion as the votes cast by other holders of the Issuer’s Common Stock. Of the 567,742 shares, Tang Capital Partners, LP controls the voting of 191,142 shares based on its proportional ownership in the Issuer.

     

    The percentages used herein are based upon 38,490,336 shares of Common Stock outstanding as of October 29, 2021.

     

    Tang Capital Management, LLC, as the general partner of Tang Capital Partners, LP, may be deemed to beneficially own the shares of the Issuer’s Common Stock owned by Tang Capital Partners, LP. Tang Capital Management, LLC shares voting and dispositive power over such shares with Tang Capital Partners, LP and Kevin Tang.


      Page 5 of 8 
     

     

    Kevin Tang, as the manager of Tang Capital Management, LLC, may be deemed to beneficially own the shares of the Issuer’s Common Stock beneficially owned by Tang Capital Partners, LP. Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners, LP and Tang Capital Management, LLC.

     

    (b)          Voting and disposition powers:

     

    Sole power to vote or direct the vote:

     

    Tang Capital Partners, LP 0 shares
    Tang Capital Management, LLC 0 shares
    Kevin Tang 0 shares

     

    Shared power to vote or direct the vote:

     

    Tang Capital Partners, LP

    12,958,577 shares

    Tang Capital Management, LLC

    12,958,577 shares

    Kevin Tang

    12,958,577 shares

     

    Sole power to dispose or direct the disposition:

     

    Tang Capital Partners, LP 0 shares
    Tang Capital Management, LLC 0 shares
    Kevin Tang 0 shares

     

    Shared power to dispose or direct the disposition:

     

    Tang Capital Partners, LP

    12,767,435 shares

    Tang Capital Management, LLC

    12,767,435 shares

    Kevin Tang

    12,767,435 shares

     

    (c)          The Reporting Persons have engaged in the following transactions in the Issuer’s Common Stock during the last 60 days.

     

      Page 6 of 8 
     

     

    Entity Transaction Trade Date Shares Price/Share
             
    Tang Capital Partners, LP Sale November 17, 2021 468,849 $2.65831
    Tang Capital Partners, LP Sale November 17, 2021 31,151 $1.99412
    Tang Capital Partners, LP Sale November 17, 2021 500,000 $2.01613
    Tang Capital Partners, LP Sale November 17, 2021 287,577 $2.19854
    Tang Capital Partners, LP Sale November 18, 2021 212,423 $1.97085
    Tang Capital Partners, LP Sale November 18, 2021 500,000 $1.88126
    Tang Capital Partners, LP Sale November 18, 2021 381,842 $1.89257
    Tang Capital Partners, LP Sale November 19, 2021

    365,289

    $1.91618

     

    (d)       N/A.

     

    (e)       N/A.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.

     

    The information previously provided in response to Item 6 is hereby amended and restated by replacing the text thereof in its entirety with the following:

     

    Reference is made to the relationships described in Item 5(a) of this Statement.

     

    The Reporting Persons have entered into a Joint Filing Agreement. See Item 2.

     

    The shares reported as beneficially owned by the Reporting Persons include a total of 345,427 shares of Common Stock that are held of record by Holdings as of the date this Statement is filed. Holdings has granted a proxy to: (a) Tang Capital Partners, LP giving Tang Capital Partners, LP the authority to vote 154,285 shares; and (b) the Issuer giving the Issuer the authority to vote 567,742 shares in the same proportion as the votes cast by other holders of the Issuer’s Common Stock. Of the 567,742 shares, Tang Capital Partners, LP controls the voting of 191,142 shares based on its proportional ownership in the Issuer. The proxy terminates upon the transfer or distribution of the shares subject to the proxy or the written agreement of the parties. The foregoing description is only a summary and is qualified in its entirety by reference to the complete text of the proxy, the form of which is filed as Exhibit 2 hereto.

     

    Any of the Reporting Persons may from time to time acquire or dispose of Issuer securities. Such acquisitions or dispositions may be made in the open market or in privately negotiated transactions.

     

     __________________________

     

    1 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the ranges set forth in Footnotes 1 through 8 herein.

    2 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.

    3 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.

    4 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.

    5 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.

    6 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.

    7 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.

    8 The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.

     

      Page 7 of 8 
     

      

    SIGNATURES

     

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the following Reporting Persons certifies that the information set forth in this statement is true, complete and correct.

     

     

    November 19, 2021

     

      Tang Capital Partners, LP  
           
           
      By: Tang Capital Management, LLC  
           
      By: /s/ Kevin Tang  
        Kevin Tang, Manager  
           
           
      Tang Capital Management, LLC  
           
      By: /s/ Kevin Tang  
        Kevin Tang, Manager  
           
           
      /s/ Kevin Tang  
      Kevin Tang  

     

     

    Page 8 of 8

     

     

     

    Get the next $ODT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ODT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ODT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Odonate Announces Expected Delisting of Its Stock

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC ("Nasdaq") notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the "SEC"), which will remove Odonate's securities from listing and registration on The

      1/7/22 9:00:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Planned Return of Capital to Stockholders through Share Repurchase Plan

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced that it will commence a share repurchase plan for up to 20 million shares in order to return capital to stockholders. This action is in connection with the Company's previously announced decision to discontinue the development of tesetaxel. Repurchases may be made from time to time at the Company's discretion. The plan has no time limit and can be discontinued at any time. There can be no assurance as to the timing or number of shares of any repurchases. As of September 30, 2021, as reported in its recently filed Form 10-Q, the Company had total stockholders' equity of $71.4 million, or $1.85 per share, based on 38.5 million shares ou

      11/17/21 7:45:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Odonate Therapeutics downgraded by Jefferies with a new price target

      Jefferies downgraded Odonate Therapeutics from Buy to Hold and set a new price target of $4.00 from $45.00 previously

      3/22/21 12:46:40 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics downgraded by Cowen

      Cowen downgraded Odonate Therapeutics from Outperform to Market Perform

      3/22/21 11:27:45 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Ecor1 Capital, Llc bought $308,662 worth of shares (185,941 units at $1.66) and sold $9,741,063 worth of shares (5,887,610 units at $1.65)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      12/10/21 6:50:07 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Boxer Capital, Llc sold $623,340 worth of shares (400,000 units at $1.56)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/24/21 6:00:33 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Davis Aaron I. sold $2,499,948 worth of shares (1,200,000 units at $2.08)

      4 - Odonate Therapeutics, Inc. (0001717452) (Issuer)

      11/19/21 7:22:38 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Odonate Therapeutics Inc.

      25-NSE - Odonate Therapeutics, Inc. (0001717452) (Subject)

      1/25/22 5:30:50 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      1/7/22 9:00:35 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Odonate Therapeutics, Inc. (0001717452) (Filer)

      11/18/21 5:00:34 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Financials

    Live finance-specific insights

    See more
    • Odonate Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and nine months ended September 30, 2021. As of September 30, 2021, Odonate had $95.0 million in cash compared to $157.3 million as of December 31, 2020. Odonate's cash used in operating activities for the three and nine months ended September 30, 2021 was $15.1 million and $63.0 million, respectively. Odonate's net loss for the three and nine months ended September 30, 2021 was $14.0 million and $69.8 million, or $0.37 and $1.85 per share, respectively, compared to $30.5 million and $94.1 million, or $0.93 and $3.00 per share, respectively, for the same periods in 2020. About Odonate Therapeutics, In

      11/10/21 5:15:00 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three and Six Months Ended June 30, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three and six months ended June 30, 2021. In March 2021, Odonate announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. As of June 30, 2021, Odonate has transitioned all patients in tesetaxel studies to appropriate alternative therapies or facilitated continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of June 30, 2021, Odonate had $110.1 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the six months en

      7/27/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Odonate Therapeutics Announces Financial Results for the Three Months Ended March 31, 2021

      Odonate Therapeutics, Inc. (NASDAQ:ODT) today announced financial results for the three months ended March 31, 2021. Odonate recently announced the discontinuation of development of tesetaxel and its intent to wind down tesetaxel-related operations. Odonate is working with clinical sites to transition patients in ongoing tesetaxel studies to appropriate alternative therapies or facilitate continuation of treatment with tesetaxel under compassionate use programs where appropriate. As of March 31, 2021, Odonate had $133.2 million in cash compared to $157.3 million as of December 31, 2020. This decrease in cash resulted primarily from cash used in operating activities for the three months en

      5/14/21 8:30:00 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ODT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13G/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      12/10/21 5:24:12 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/26/21 5:01:04 PM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13D/A filed by Odonate Therapeutics, Inc. (Amendment)

      SC 13D/A - Odonate Therapeutics, Inc. (0001717452) (Subject)

      11/22/21 11:08:29 AM ET
      $ODT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care